Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Prices $12M Offering of Stock

NEW YORK (GenomeWeb News) – CombiMatrix today priced its public offering of 12,000 units of preferred of Series D convertible preferred stock and warrants at a price of $1,000 per unit.

Gross proceeds from the offering are $12 million, with net proceeds anticipated to be $10.8 million. The array-based molecular diagnostics developer said that it expects to close the offering on or around Dec. 20.

Each unit being sold by CombiMatrix consists of one share of Series D convertible preferred stock, which is convertible into 485.4369 shares of common stock at a conversion price of $2.06 per share, and one warrant to purchase 485.4369 shares of common stock at an exercise price of $3.12 per share.

In Tuesday morning trade on the Nasdaq, shares of CombiMatrix were down around 18 percent at $2.35.

The Scan

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.

EHR Quality Improvement Study Detects Demographic-Related Deficiencies in Cancer Family History Data

In a retrospective analysis in JAMA Network Open, researchers find that sex, ethnicity, language, and other features coincide with the quality of cancer family history information in a patient's record.

Inflammatory Bowel Disease Linked to Gut Microbiome Community Structure Gradient in Meta-Analysis

Bringing together data from prior studies, researchers in Genome Biology track down microbial taxa and a population structure gradient with ties to ulcerative colitis or Crohn's disease.

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.